



Notice of Annual General Meeting

Radiopharm Theranostics Limited ACN 647 877 889

Notice of Annual General Meeting

Radiopharm Theranostics Limited ACN 647 877 889

Notice is given that the Annual General Meeting of Radiopharm Theranostics Limited ACN 647 877 889 (**Company**) will be held at:

Location	Level 3, 62 Lygon Street, Carlton, Victoria 3053 and virtually (online) by Zoom conference
Date	Wednesday, 16 November 2022
Time	10:00am (Sydney time) Registration from 9:45am (Sydney time)

Zoom meeting details

The AGM will be webcast live via an online platform. To participate you will need a desktop or mobile/tablet device with internet access. When you log onto the online platform to register to attend the AGM, you will need to provide your details (including SRN or HIN) to be verified as a Shareholder.

All Shareholders have the opportunity to attend and participate in the 2022 Annual General Meeting (**Meeting**) online via internet connection (using a computer, laptop, tablet or smartphone).

To register for the meeting, please click the link below:

https://us02web.zoom.us/webinar/register/WN_jW7vtbhDS_CmAE97r5fbQw

After registering, you will receive a confirmation email containing information about joining the Meeting.

For further details and instructions, please see the online meeting guide located on the Company website containing details on attending and voting at the Annual General Meeting.

If Shareholders are unable to attend the Meeting using the online platform they are encouraged to alternatively, return the proxy form to the Company in accordance with the instructions thereon.

Returning the proxy form will not preclude a Shareholder from attending and voting at the Meeting utilising the online platform should they elect to do so.

Shareholder Questions

In accordance with the Corporations Act, reasonable opportunity will be given to Shareholders at the Meeting to ask questions about, or make comments on, the Meeting, the Company's management and the Remuneration Report, or the Company itself.

A reasonable opportunity will also be given to Shareholders of the Meeting to ask the Company's auditor, Grant Thornton Audit Pty Ltd (**Auditor**), questions relevant to the auditor's report or conduct of the audit, the preparation and contents of the audit report, the content of the audit, the independence of the Auditor in relation to the conduct of the audit and the accounting policies adopted by the Company in preparation of the financial statements. The Auditor will be given a reasonable opportunity to answer written questions submitted by Shareholders of the Meeting.

In accordance with section 250PA of the Corporations Act, written questions for the Auditor must be submitted to the Company by no later than the fifth business day before the day on which the Meeting is to be held. In this case, no later than 9 November 2022.

Ordinary Business

Financial Statements and Reports

To consider and receive the financial report, the Directors' report and the auditor's report for the year ended 30 June 2022.

Resolution 1 - Remuneration Report

To consider and, if in favour, pass the following resolution in accordance with section 250R(2) Corporations Act:

- 1 *'That the Remuneration Report be adopted.'*

Note: This resolution shall be determined under section 250R(2) Corporations Act. Votes must not be cast on this resolution by Key Management Personnel and closely related parties in contravention of section 250R or 250BD Corporations Act. Restrictions also apply to votes cast as proxy unless exceptions apply.

The Directors abstain, in the interests of corporate governance, from making a recommendation in relation to this resolution.

Under the Corporations Act, the vote on the Remuneration Report is advisory only and does not bind the Directors or the Company.

Resolution 2 – Re-election of Director – Mr Paul Hopper

To consider and, if in favour, pass the following resolution as an ordinary resolution:

- 2 *'That, Mr Paul Hopper, a Director, who retires by rotation in accordance with Listing Rule 14.4 and rule 19.3 of the Company's constitution (**Constitution**), and being eligible, be re-elected as a Director of the Company.'*

Note: Further information about the candidate appears in the Explanatory Memorandum.

The Directors (with Mr Paul Hopper abstaining) unanimously recommend that you vote in favour of this resolution.

Resolution 3 – Election of Director – Ms Hester Larkin

To consider and, if in favour, pass the following resolution as an ordinary resolution:

- 3 *'That, Ms Hester Larkin who, having previously been appointed to fill a casual vacancy, retires in accordance with Listing Rule 14.4 and rule 19.3 of the Company's Constitution and having consented to act and being eligible, be elected as Director of the Company.'*

Note: Further information about the candidate appears in the Explanatory Memorandum.

The Directors (with Ms Hester Larkin abstaining) unanimously recommend that you vote in favour of this resolution.

Resolution 4 – Election of Director – Dr Leila Alland

To consider and, if in favour, pass the following resolution as an ordinary resolution:

- 4 *'That, Dr Leila Alland who, having previously been appointed to fill a casual vacancy, retires in accordance with Listing Rule 14.4 and rule 19.3 of the Company's Constitution and having consented to act and being eligible, be elected as Director of the Company.'*

Note: Further information about the candidate appears in the Explanatory Memorandum.

The Directors (with Dr Leila Alland abstaining) unanimously recommend that you vote in favour of this resolution.

Special business

Resolution 5 – Approval to issue of Options to Director – Ms Hester Larkin

To consider and, if in favour, to pass the following as an ordinary resolution:

- 5 *'That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the granting of 1,900,002 unlisted options to Ms Hester Larkin, or her nominee, under the Company's Omnibus Incentive Plan, on the terms set out in the Explanatory Memorandum.'*

Note: if approval is obtained under Listing Rule 10.14, approval is not required under Listing Rule 7.1 or Listing Rule 10.11, as set out in the Explanatory Memorandum.

The Directors (with Ms Hester Larkin abstaining) unanimously recommend that you vote in favour of this resolution.

Resolution 6 – Approval to issue of Options to Director – Dr Leila Alland

To consider and, if in favour, to pass the following as an ordinary resolution:

- 6 *'That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the granting of 1,900,002 unlisted options to Dr Leila Alland, or her nominee, under the Company's Omnibus Incentive Plan, on the terms set out in the Explanatory Memorandum.'*

Note: if approval is obtained under Listing Rule 10.14, approval is not required under Listing Rule 7.1 or Listing Rule 10.11, as set out in the Explanatory Memorandum.

The Directors (with Dr Leila Alland abstaining) unanimously recommend that you vote in favour of this resolution.

Resolution 7 – Approval to issue of Options to Director – Mr Ian Turner

To consider and, if in favour, to pass the following as an ordinary resolution:

- 7 *'That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the granting of 1,651,510 unlisted options to Mr Ian Turner, or his nominee, under the Company's Omnibus Incentive Plan, on the terms set out in the Explanatory Memorandum.'*

Note: if approval is obtained under Listing Rule 10.14, approval is not required under Listing Rule 7.1 or Listing Rule 10.11, as set out in the Explanatory Memorandum.

The Directors (with Mr Ian Turner abstaining) unanimously recommend that you vote in favour of this resolution.

Resolution 8 – Approval to issue of Options to Director – Mr Paul Hopper

To consider and, if in favour, to pass the following as an ordinary resolution:

- 8 *'That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the granting of 4,210,329 unlisted options to Mr Paul Hopper, or his nominee, under the Company's Omnibus Incentive Plan, on the terms set out in the Explanatory Memorandum.'*

Note: if approval is obtained under Listing Rule 10.14, approval is not required under Listing Rule 7.1 or Listing Rule 10.11, as set out in the Explanatory Memorandum.

The Directors (with Mr Paul Hopper abstaining) unanimously recommend that you vote in favour of this resolution.

Resolution 9 – Approval to issue Options to Director – Mr Riccardo Canevari

To consider and, if in favour, to pass the following as an ordinary resolution:

- 9 *'That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the granting of 12,505,088 unlisted options to Mr Riccardo Canevari, or his nominee, under the Company's Omnibus Incentive Plan, on the terms set out in the Explanatory Memorandum.'*

Note: if approval is obtained under Listing Rule 10.14, approval is not required under Listing Rule 7.1 or Listing Rule 10.11, as set out in the Explanatory Memorandum.

The Directors (with Mr Riccardo Canevari abstaining) unanimously recommend that you vote in favour of this resolution.

Resolution 10 – Approval of 10% capacity under Listing Rule 7.1A

To consider and, if in favour, to pass the following as a special resolution:

- 10 *'That, for the purposes of Listing Rule 7.1A and for all other purposes, Shareholders approve the Company having the additional capacity to issue equity securities up to 10% of the issued capital of the Company (at the time of issue) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 over a 12 month period from the date of the Annual General Meeting, at a price no less than that determined pursuant to Listing Rule 7.1A.3 and otherwise on the terms and conditions set out in the Explanatory Memorandum.'*

The Directors unanimously recommend that you vote in favour of this resolution.

Resolution 11 – Renewal of the Omnibus Incentive Plan

To consider and, if in favour, to pass the following as an ordinary resolution:

- 11 *'That for the purpose of Listing Rule 7.2, Exception 13 and sections 200B and 200E of the Corporations Act and for all other purposes, the Company hereby approves the renewal of the Company's Employee Share Option Plan, the terms and conditions of which are summarised in the Explanatory Memorandum.'*

The Directors abstain, in the interests of corporate governance from making a recommendation in relation to this resolution.

Dated: 14 October 2022

By order of the Board

Phillip Hains
Company Secretary

Voting Exclusion Statement

Corporations Act

Resolution 1 - The Company will disregard votes cast by a member of the Key Management Personnel details of whose remuneration are included in the Remuneration Report, or a closely related party of such a member, in contravention of section 250R or 250BD Corporations Act. Restrictions also apply to votes cast as proxy unless exceptions apply.

For the purposes of section 224 Corporations Act, the Company will not disregard a vote if:

- (a) it is cast by a person as a proxy appointed in writing that specifies how the proxy is to vote on the proposed resolution; and
- (b) it is not cast on behalf of a related party or associate of a related party of the Company to whom the resolution would permit a financial benefit to be given or an associate of such a related party.

Listing Rules

In accordance with the Listing Rule 14.11, the Company will disregard votes cast in favour of the resolution by or on behalf of:

Resolution 5	Ms Hester Larkin (or any of her associates), being a director of the Company who is eligible to participate in the employee incentive scheme in respect of which approval is sought, and any other person who in ASX's opinion should be disregarded.
Resolution 6	Dr Leila Alland (or any of her associates), being a director of the Company who is eligible to participate in the employee incentive scheme in respect of which approval is sought, and any other person who in ASX's opinion should be disregarded.
Resolution 7	Mr Ian Turner (or any of his associates), being a director of the Company who is eligible to participate in the employee incentive scheme in respect of which approval is sought, and any other person who in ASX's opinion should be disregarded.
Resolution 8	Mr Paul Hopper (or any of his associates), , being an associate of a director of the Company (Mr Paul Hopper) who is eligible to participate in the employee incentive scheme in respect of which approval is sought, and any other person who in ASX's opinion should be disregarded.
Resolution 9	Mr Riccardo Canevari (or any of his associates), being a director of the Company who is eligible to participate in the employee incentive scheme in respect of which approval is sought, and any other person who in ASX's opinion should be disregarded.
Resolution 10	a person, or any associate of that person, who is expected to participate in, or will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of Shares). NB. In accordance with Listing Rule 14.11 and the relevant note under that rule concerning Rule 7.1A, as at the date of this Notice of Meeting it is not known who may participate in the proposed issue (if any). On that basis, no security holders are currently excluded.

Resolution 11

any person who is eligible to participate in the amended Omnibus Incentive Plan and each of their associates.

However, this does not apply to a vote cast in favour of a resolution by:

- (a) a person as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to the proxy or attorney to vote on the resolution in that way; or
- (b) the chair of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction given to the chair to vote on the resolution as the chair decides; or
- (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the resolution; and
 - (ii) the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

Notes

- (a) Terms used in this Notice of Meeting which are defined in the Explanatory Memorandum have the meaning given to them in the Explanatory Memorandum.
- (b) Subject to the Corporations Act, including sections 250R and 250BD, a Shareholder who is entitled to attend and cast a vote at the meeting is entitled to appoint a proxy.
- (c) The proxy need not be a Shareholder of the Company. A Shareholder who is entitled to cast two or more votes may appoint two proxies and may specify the proportion or number of votes each proxy is appointed to exercise.
- (d) If you wish to appoint a proxy and are entitled to do so, then complete and return the **attached** proxy form to the Company's share registry Automic Registry Service Limited as detailed in the attached proxy form.
- (e) You can also lodge your proxy online at <https://investor.automic.com.au/#/loginsah> which is also located on the front of the accompanying proxy form. Alternatively, you can scan the QR code with your mobile device.
- (f) To be effective, the proxy must be received at the share registry of the Company no later than 10.00am (Sydney time) on Monday 14 November 2022 (48 hours before the commencement of the meeting).
- (g) A corporation may elect to appoint a representative in accordance with the Corporations Act in which case the Company will require written proof of the representative's appointment which must be lodged with or presented to the Company before the meeting.
- (h) The Company has determined under regulation 7.11.37 Corporations Regulations that for the purpose of voting at the meeting or adjourned meeting, securities are taken to be held by those persons recorded in the Company's register of Shareholders as at 7:00 pm (Sydney time) on Monday 14 November 2022.
- (i) If you have any queries, including how to cast your votes, please contact the Company's registered office on 03 9824 5254 (within Australia) or +61 3 9824 5254 (outside Australia) during business hours.

Explanatory Memorandum

This Explanatory Memorandum accompanies the notice of Annual General Meeting of the Company to be held at Level 3, 62 Lygon Street, Carlton, Victoria 3053 and virtually (online) by Zoom on Wednesday, 16 November 2022 at 10.00am (Sydney time).

The Explanatory Memorandum has been prepared to assist Shareholders in determining how to vote on the resolutions set out in the Notice of Meeting and is intended to be read in conjunction with the Notice of Meeting.

Financial Statements and Reports

- 12 The *Corporations Act 2001* (Cth) (**Corporations Act**) requires that the report of the Directors, the auditor's report and the financial report be laid before the Annual General Meeting.
- 13 Apart from the matters involving remuneration which are required to be voted upon, neither the Corporations Act nor the Constitution requires a vote of Shareholders at the Annual General Meeting on the financial statements and reports.
- 14 Shareholders will be given a reasonable opportunity at the meeting to raise questions and make comments on these reports.
- 15 In addition to asking questions at the meeting, Shareholders may address written questions to the chairman about the management of the Company or to the Company's auditor, Grant Thornton Australia, if the question is relevant to:
 - (a) the content of the auditor's report; or
 - (b) the conduct of its audit of the annual financial report to be considered at the meeting.

Note: Under section 250PA(1) Corporations Act, a Shareholder must submit the question to the Company no later than the fifth business day before the day on which the Annual General Meeting is held.

- 16 Written questions for the auditor must be delivered by 5:00pm on Wednesday 9 November 2022. Please send any written questions for Grant Thornton Australia to:

The Company Secretary
PO Box 655
Carlton South, VIC 3053

or via email to: info@thecfo.com.au

Resolution 1: Remuneration Report

- 17 The Remuneration Report is contained in the Annual Report. A copy is available on the Company's website.
- 18 The Corporations Act requires that the Remuneration Report be put to a vote of Shareholders.
- 19 The resolution of Shareholders is advisory only and not binding on the Company. The Board will take the discussion at the meeting into consideration when determining the Company's remuneration policy and appropriately respond to any concerns Shareholders may raise in relation to remuneration issues.

20 The Remuneration Report:

- (a) reports and explains the remuneration arrangements in place for non-executive Directors, executive Directors and senior management; and
- (b) explains Board policies in relation to the nature and value of remuneration paid to non-executive Directors, executives and senior managers within the Company.

21 The Chairman will give Shareholders a reasonable opportunity to ask questions about, or to make comments on, the Remuneration Report.

Directors' Recommendation

22 As the resolution relates to matters including the remuneration of the Directors, the Board, as a matter of corporate governance and in accordance with the spirit of section 250R(4) Corporations Act, makes no recommendation regarding this resolution.

Resolution 2: Re-election of Director – Mr Paul Hopper

23 Mr Paul Hopper was appointed as a Director of the Company on 11 February 2021 and retires in accordance with rule 19.3 of the Company's Constitution and Listing Rule 14.4 and stands for election.

24 Mr Paul Hopper has over 25 years experience in the medical, healthcare and life sciences sectors. Focused on start-up and rapid growth companies, he has served as either Founder, Chairman, non-executive director, or Chief Executive Officer, of more than fifteen companies in the US, Australia and Asia.

Directors' Recommendation

25 The Directors (with Mr Hopper abstaining), unanimously recommend the appointment of Mr Paul Hopper to the Board.

Resolution 3: Election of Director – Ms Hester Larkin

26 Ms Hester Larkin was previously appointed to fill a casual vacancy for the Company on 3 February 2022 and retires in accordance with rule 19.3 of the Company's Constitution and Listing Rule 14.4 and stands for election.

27 Ms Hester Larkin has a 30-year career in both pharmaceuticals and nuclear medicine across Europe, Middle East and Africa, including over 12 years of experience in senior leadership roles in the industry. Ms Hester Larkin has a proven track record of delivering significant corporate revenues and earnings and leading successful product launches of proprietary pharmaceuticals and imaging agents in oncology, cardiology, neurology and HIV.

Directors' Recommendation

28 The Directors (with Ms Larkin abstaining), unanimously recommend the appointment of Ms Hester Larkin to the Board.

Resolution 4: Election of Director – Dr Leila Alland

29 Dr Leila Alland was previously appointed to fill a casual vacancy for the Company on 6 June 2022 and retires in accordance with rule 19.3 of the Company's Constitution and Listing Rule 14.4 and stands for election.

- 30 Dr Leila Alland is a paediatric haematologist-oncologist with a strong track record in developing oncology drug products. Over the course of her career, Dr Leila Alland has held leadership positions where she contributed to multiple successful drug approvals. She serves on the board of several pharmaceutical companies and is a member of the Scientific Advisory Council of Columbia University's Center for Radiological Research. Previously, she served as Chief Medical Officer of Affimed, a clinical stage immune-oncology company.

Directors' Recommendation

- 31 The Directors (with Dr Leila abstaining), unanimously recommend the appointment of Dr Leila Alland to the Board.

Resolution 5: Approval to issue Options to Director – Ms Hester Larkin

- 32 On 3 February 2022, the Company agreed to grant, subject to Shareholder approval, Ms Hester Larkin with 1,900,002 (in aggregate) unlisted options (**Incentive Options**) pursuant to the terms of the Company's Omnibus Incentive Plan.

Chapter 2E of the Corporations Act

- 33 Chapter 2E of the Corporations Act requires that for a public company, or an entity that the public company controls, to give a financial benefit to a related party of the public company, the public company or entity must:
- (a) obtain the approval of the public company's members in the manner set out in sections 217 to 227 of the Corporations Act; and
 - (b) give the benefit within 15 months following such approval,
- unless the giving of the financial benefit falls within an exception set out in sections 210 to 216 of the Corporations Act.
- 34 The issue of the Incentive Options to Ms Hester Larkin (or her nominee) constitutes giving a financial benefit and Ms Hester Larkin is a related party of the Company by virtue of being a Director.
- 35 The Directors (with Ms Hester Larkin abstaining) consider that Shareholder approval pursuant to Chapter 2E of the Corporations Act is not required in respect of the issue of Incentive Options, because the agreement to issue the Incentive Options, reached as part of the remuneration package Ms Hester Larkin, is considered reasonable remuneration in the circumstances and was negotiated on an arm's length basis.

Listing Rule 10.14

- 36 Listing Rule 10.14 provides that an entity must not permit any of the following persons to acquire equity securities under an employee incentive scheme without the approval of the holders of its ordinary securities:
- 10.14.1 a director of the entity;
 - 10.14.2 an associate of a director of the entity; or

10.14.3 a person whose relationship with the entity or a person referred to in Listing Rules 10.14.1 to 10.14.2 is such that, in ASX's opinion, the acquisition should be approved by security holders.

37 The issue of the Incentive Options to Ms Hester Larkin falls within Listing Rule 10.14.1 and therefore requires the approval of Shareholders under Listing Rule 10.14.

38 Resolution 5 seeks the required Shareholder approval for the issue of the Incentive Options under and for the purposes of Listing Rule 10.14.

Technical information required by Listing Rule 14.1A

39 If Resolution 5 is passed, the Company will be able to proceed with the issue of the Incentive Options to Ms Hester Larkin under the Omnibus Incentive Plan. As approval pursuant to Listing Rule 7.1 is not required for the issue of the Incentive Options (because approval is being obtained under Listing Rule 10.14), the issue of the Incentive Options will not use up any of the Company's 15% annual placement capacity. Once approval is obtained pursuant to Listing Rule 10.14, the Company is entitled to rely on Listing Rule 10.12 (Exception 4) as an exception to any requirement that may otherwise apply requiring Shareholder approval under Listing Rule 10.11.

40 If Resolution 5 is not passed, the Company will not be able to proceed with the issue of the Incentive Options to Ms Hester Larkin under the Omnibus Incentive Plan and may need to agree alternative forms of remuneration with Ms Hester Larkin.

Technical information required by Listing Rule 10.15

41 Pursuant to and in accordance with the requirements of Listing Rule 10.15, the following information is provided in relation to Resolution 5:

- (a) the Incentive Options will be issued to Ms Hester Larkin (or her nominee), who falls within the category set out in Listing Rule 10.14.1 by virtue of Ms Hester Larkin being a Director;
- (b) the maximum number of Incentive Options to be issued is 1,900,002;
- (c) the current total remuneration package for Ms Hester Larkin (excluding the value of the proposed Incentive Options) is \$65,000 per annum, comprising of directors' and committee fees of \$65,000 (excluding superannuation) and options of \$Nil. If the Incentive Options are issued, the total remuneration package of Ms Hester Larkin will increase by \$170,920 to \$235,920, being the value of the Incentive Options (based on the Black-Scholes methodology);
- (d) other than the Incentive Options, the Company has not previously issued any Options to Ms Hester Larkin under the Omnibus Incentive Plan;
- (e) a summary of the material terms of the Incentive Options are set out in Schedule 1;
- (f) the Company has chosen to issue the Incentive Options (as opposed to fully paid ordinary securities) to Ms Hester Larkin for the following reasons:
 - (i) the Incentive Options are unquoted, therefore, the issue of the Incentive Options has no immediate dilutionary impact on Shareholders;
 - (ii) the issue of Incentive Options to Ms Hester Larkin will align the interests of Ms Hester Larkin with those of Shareholders;

- (iii) the issue of the Incentive Options is a reasonable and appropriate method to provide cost effective remuneration as the non-cash form of this benefit will allow the Company to spend a greater proportion of its cash reserves on its operations than it would if alternative cash forms of remuneration were given to Ms Hester Larkin; and
- (iv) it is not considered that there are any significant opportunity costs to the Company or benefits foregone by the Company in issuing the Incentive Options on the terms proposed;
- (g) the Company values the Incentive Options (in aggregate) to be issued to Ms Hester Larkin at \$170,920 (being approximately \$0.09 per Incentive Option) based on the Black-Scholes methodology using the closing price of \$0.18 (being the closing share price at 6 October 2022,), exercise price per Incentive Option of \$0.60, life of the Incentive Options of 4 years, a risk free interest rate of 4.0% and assumed volatility of 100%. The above is based on inputs at 6 October 2022. This information is provided for the purposes of the applicable Listing Rule using the stated assumptions which may not apply at the time of the issue of the options and the actual value may be different. The value under accounting standards will be calculated based on inputs at the date of Shareholder approval;
- (h) if this Resolution 5 is passed, it is intended that the Incentive Options will be issued to Ms Hester Larkin (or her nominee) within 30 days after this Annual General Meeting, but in any event no later than 3 years after the date of this Annual General Meeting (or such later date as permitted by any ASX waiver or modification of the Listing Rules);
- (i) the issue price of the Incentive Options will be nil, as such no funds will be raised from the issue of the Incentive Options (other than in respect of funds received on exercise of the Incentive Options where the Cashless Exercise Facility is not used);
- (j) a summary of the material terms of the Omnibus Incentive Plan are set out in Schedule 3;
- (k) no loan is being made to Ms Hester Larkin in connection with the acquisition of the Incentive Options;
- (l) details of any Options issued under the Omnibus Incentive Plan will be published in the annual report of the Company relating to the period in which they were issued, along with a statement that approval for the issue was obtained under Listing Rule 10.14; and
- (m) any additional persons covered by Listing Rule 10.14 who become entitled to participate in an issue of Options under the Omnibus Incentive Plan after Resolution 5 is approved and who were not named in this Notice will not participate until approval is obtained under Listing Rule 10.14.

Directors' Recommendation

- 42 The Directors (with Ms Hester Larkin abstaining) unanimously recommend that you vote in favour of this resolution.

Resolution 6: Approval to issue Options to Director – Dr Leila Alland

- 43 On 6 June 2022, the Company agreed to grant, subject to Shareholder approval, Dr Leila Alland with 1,900,002 (in aggregate) Incentive Options pursuant to the terms of the Company's Omnibus Incentive Plan.

Chapter 2E of the Corporations Act

- 44 For the purposes of Chapter 2E of the Corporations act (as summarised at paragraph 33), the issue of the Incentive Options to Dr Leila Alland (or her nominee) constitutes giving a financial benefit and Dr Leila Alland is a related party of the Company by virtue of being a Director.
- 45 The Directors (with Dr Leila Alland abstaining) consider that Shareholder approval pursuant to Chapter 2E of the Corporations Act is not required in respect of the issue of Incentive Options, because the agreement to issue the Incentive Options, reached as part of the remuneration package Dr Leila Alland, is considered reasonable remuneration in the circumstances and was negotiated on an arm's length basis.

Listing Rule 10.14

- 46 For the purposes of Listing Rule 10.14 (as summarised at paragraph 36) the issue of the Incentive Options to Dr Leila Alland falls within Listing Rule 10.14.1 and therefore requires the approval of Shareholders under Listing Rule 10.14.
- 47 Resolution 6 seeks the required Shareholder approval for the issue of the Incentive Options under and for the purposes of Listing Rule 10.14.

Technical information required by Listing Rule 14.1A

- 48 If Resolution 6 is passed, the Company will be able to proceed with the issue of the Incentive Options to Dr Leila Alland under the Omnibus Incentive Plan. As approval pursuant to Listing Rule 7.1 is not required for the issue of the Incentive Options (because approval is being obtained under Listing Rule 10.14), the issue of the Incentive Options will not use up any of the Company's 15% annual placement capacity. Once approval is obtained pursuant to Listing Rule 10.14, the Company is entitled to rely on Listing Rule 10.12 (Exception 4) as an exception to any requirement that may otherwise apply requiring Shareholder approval under Listing Rule 10.11.
- 49 If Resolution 5 is not passed, the Company will not be able to proceed with the issue of the Incentive Options to Dr Leila Alland under the Omnibus Incentive Plan and may need to agree alternative forms of remuneration with Dr Leila Alland.

Technical information required by Listing Rule 10.15

- 50 Pursuant to and in accordance with the requirements of Listing Rule 10.15, the following information is provided in relation to Resolution 6:
- (a) the Incentive Options will be issued to Dr Leila Alland (or her nominee), who falls within the category set out in Listing Rule 10.14.1 by virtue of Dr Leila Alland being a Director;
 - (b) the maximum number of Incentive Options to be issued is 1,900,002;
 - (c) the current total remuneration package for Dr Leila Alland (excluding the value of the proposed Incentive Options) is \$60,000 per annum, comprising of directors' and committee fees of \$60,000 (excluding superannuation) and options of \$Nil. If the Incentive Options are issued, the total remuneration package of Dr Leila Alland will increase by \$170,920 to \$230,920, being the value of the Incentive Options (based on the Black-Scholes methodology);
 - (d) other than the Incentive Options, the Company has not previously issued any Options to Dr Leila Alland under the Omnibus Incentive Plan;
 - (e) a summary of the material terms of the Incentive Options are set out in Schedule 1;

- (f) the Company has chosen to issue the Incentive Options (as opposed to fully paid ordinary securities) to Dr Leila Alland for the following reasons:
 - (i) the Incentive Options are unquoted, therefore, the issue of the Incentive Options has no immediate dilutionary impact on Shareholders;
 - (ii) the issue of Incentive Options to Dr Leila Alland will align the interests of Dr Leila Alland with those of Shareholders;
 - (iii) the issue of the Incentive Options is a reasonable and appropriate method to provide cost effective remuneration as the non-cash form of this benefit will allow the Company to spend a greater proportion of its cash reserves on its operations than it would if alternative cash forms of remuneration were given to Dr Leila Alland; and
 - (iv) it is not considered that there are any significant opportunity costs to the Company or benefits foregone by the Company in issuing the Incentive Options on the terms proposed;
- (g) the Company values the Incentive Options (in aggregate) to be issued to Dr Leila Alland at \$170,920 (being approximately \$0.09 per Incentive Option) based on the Black-Scholes methodology using the closing price of \$0.18 (being the closing share price at 6 October 2022), exercise price per Incentive Option of \$0.60, life of the Incentive Options of 4 years, a risk free interest rate of 4.0% and assumed volatility of 100%. The above is based on inputs at 6 October 2022. This information is provided for the purposes of the applicable Listing Rule using the stated assumptions which may not apply at the time of the issue of the options and the actual value may be different. The value under accounting standards will be calculated based on inputs at the date of Shareholder approval;
- (h) if this Resolution 6 is passed, it is intended that the Incentive Options will be issued to Dr Leila Alland (or her nominee) within 30 days after this Annual General Meeting, but in any event no later than 3 years after the date of this Annual General Meeting (or such later date as permitted by any ASX waiver or modification of the Listing Rules);
- (i) the issue price of the Incentive Options will be nil, as such no funds will be raised from the issue of the Incentive Options (other than in respect of funds received on exercise of the Incentive Options where the Cashless Exercise Facility is not used);
- (j) a summary of the material terms of the Omnibus Incentive Plan are set out in Schedule 3;
- (k) no loan is being made to Dr Leila Alland in connection with the acquisition of the Incentive Options;
- (l) details of any Options issued under the Omnibus Incentive Plan will be published in the annual report of the Company relating to the period in which they were issued, along with a statement that approval for the issue was obtained under Listing Rule 10.14; and
- (m) any additional persons covered by Listing Rule 10.14 who become entitled to participate in an issue of Options under the Omnibus Incentive Plan after Resolution 5 is approved and who were not named in this Notice will not participate until approval is obtained under Listing Rule 10.14.

Directors' Recommendation

- 51 The Directors (with Dr Leila Alland abstaining) unanimously recommend that you vote in favour of this resolution.

Resolution 7: Approval to issue Options to Director – Mr Ian Turner

- 52 The Company intends to issue Mr Ian Turner 1,651,510 Incentive Options pursuant to the terms of the Company's Omnibus Incentive Plan.

Chapter 2E of the Corporations Act

- 53 For the purposes of Chapter 2E of the Corporations act (as summarised at paragraph 33), the issue of the Incentive Options to Mr Ian Turner (or his nominee) constitutes giving a financial benefit and Mr Ian Turner is a related party of the Company by virtue of being a Director.
- 54 The Directors (with Mr Ian Turner abstaining) consider that Shareholder approval pursuant to Chapter 2E of the Corporations Act is not required in respect of the issue of Incentive Options, because the agreement to issue the Incentive Options, reached as part of the remuneration package Mr Ian Turner, is considered reasonable remuneration in the circumstances and was negotiated on an arm's length basis.

Listing Rule 10.14

- 55 For the purposes of Listing Rule 10.14 (as summarised at paragraph 36) the issue of the Incentive Options to Mr Ian Turner falls within Listing Rule 10.14.1 and therefore requires the approval of Shareholders under Listing Rule 10.14.
- 56 Resolution 7 seeks the required Shareholder approval for the issue of the Incentive Options under and for the purposes of Listing Rule 10.14.

Technical information required by Listing Rule 14.1A

- 57 If Resolution 7 is passed, the Company will be able to proceed with the issue of the Incentive Options to Mr Ian Turner under the Omnibus Incentive Plan. As approval pursuant to Listing Rule 7.1 is not required for the issue of the Incentive Options (because approval is being obtained under Listing Rule 10.14), the issue of the Incentive Options will not use up any of the Company's 15% annual placement capacity. Once approval is obtained pursuant to Listing Rule 10.14, the Company is entitled to rely on Listing Rule 10.12 (Exception 4) as an exception to any requirement that may otherwise apply requiring Shareholder approval under Listing Rule 10.11.
- 58 If Resolution 7 is not passed, the Company will not be able to proceed with the issue of the Incentive Options to Mr Ian Turner under the Omnibus Incentive Plan and may need to agree alternative forms of remuneration with Mr Ian Turner.

Technical information required by Listing Rule 10.15

- 59 Pursuant to and in accordance with the requirements of Listing Rule 10.15, the following information is provided in relation to Resolution 7:
- (a) the Incentive Options will be issued to Mr Ian Turner (or his nominee), who falls within the category set out in Listing Rule 10.14.1 by virtue of Mr Ian Turner being a Director;
 - (b) the maximum number of Incentive Options to be issued is 1,651,510;
 - (c) the current total remuneration package for Mr Ian Turner (excluding the value of the proposed Incentive Options) is \$616,590 per annum, comprising of directors' fees,

committee fees and additional services of \$345,276 (excluding superannuation) and options of \$271,314. If the Incentive Options are issued, the total remuneration package of Mr Ian Turner will increase by \$110,321 to \$726,911, being the value of the Incentive Options (based on the Black-Scholes methodology);

- (d) other than the Incentive Options, the Company has not previously issued any Options to Mr Ian Turner under the Omnibus Incentive Plan;
- (e) a summary of the material terms of the Incentive Options are set out in Schedule 1;
- (f) the Company has chosen to issue the Incentive Options (as opposed to fully paid ordinary securities) to Mr Ian Turner for the following reasons:
 - (i) the Incentive Options are unquoted, therefore, the issue of the Incentive Options has no immediate dilutionary impact on Shareholders;
 - (ii) the issue of Incentive Options to Mr Ian Turner will align the interests of Mr Ian Turner with those of Shareholders;
 - (iii) the issue of the Incentive Options is a reasonable and appropriate method to provide cost effective remuneration as the non-cash form of this benefit will allow the Company to spend a greater proportion of its cash reserves on its operations than it would if alternative cash forms of remuneration were given to Mr Ian Turner; and
 - (iv) it is not considered that there are any significant opportunity costs to the Company or benefits foregone by the Company in issuing the Incentive Options on the terms proposed;
- (g) the Company values the Incentive Options (in aggregate) to be issued to Mr Ian Turner at \$110,321 (being approximately \$0.0668 per Incentive Option) based on the Black-Scholes methodology using the closing price of 0.17 (being the date the Incentive Options were granted, subject to Shareholder approval), exercise price per Incentive Option of 0.17, life of the Incentive Options of five years, a risk free interest rate of 3.23% and assumed volatility of 100%. The above is based on inputs at 1 July 2022. This information is provided for the purposes of the applicable Listing Rule using the stated assumptions which may not apply at the time of the issue of the options and the actual value may be different. The value under accounting standards will be calculated based on inputs at the date of Shareholder approval;
- (h) if this Resolution 7 is passed, it is intended that the Incentive Options will be issued to Mr Ian Turner (or his nominee) within 30 days after this Annual General Meeting, but in any event no later than 3 years after the date of this Annual General Meeting (or such later date as permitted by any ASX waiver or modification of the Listing Rules);
- (i) the issue price of the Incentive Options will be nil, as such no funds will be raised from the issue of the Incentive Options (other than in respect of funds received on exercise of the Incentive Options where the Cashless Exercise Facility is not used);
- (j) a summary of the material terms of the Omnibus Incentive Plan are set out in Schedule 3;
- (k) no loan is being made to Mr Ian Turner in connection with the acquisition of the Incentive Options;

- (l) details of any Options issued under the Omnibus Incentive Plan will be published in the annual report of the Company relating to the period in which they were issued, along with a statement that approval for the issue was obtained under Listing Rule 10.14; and
- (m) any additional persons covered by Listing Rule 10.14 who become entitled to participate in an issue of Options under the Omnibus Incentive Plan after Resolution 5 is approved and who were not named in this Notice will not participate until approval is obtained under Listing Rule 10.14.

Directors' Recommendation

- 60 The Directors (with Mr Ian Turner abstaining) unanimously recommend that you vote in favour of this resolution.

Resolution 8: Approval to issue of Options to Director – Mr Paul Hopper

- 61 The Company intends to Mr Paul Hopper, or his nominee 4,210,329 Options pursuant to the terms of the Company's Omnibus Incentive Plan (**Annual Equity Options**).

Chapter 2E of the Corporations Act

- 62 For the purposes of Chapter 2E of the Corporations act (as summarised at paragraph 33), the issue of the Annual Equity Options to Mr Paul Hopper, or his nominee, constitutes giving a financial benefit and Mr Paul Hopper is a related party of the Company by virtue of being a Director.
- 63 The Directors (with Mr Paul Hopper abstaining) consider that Shareholder approval pursuant to Chapter 2E of the Corporations Act is not required in respect of the issue of Annual Equity Options, because the agreement to issue the Annual Equity Options is considered reasonable remuneration in the circumstances and was negotiated on an arm's length basis.

Listing Rule 10.14

- 64 For the purposes of Listing Rule 10.14 (as summarised at paragraph 36) the issue of the Annual Equity Options to Mr Paul Hopper or his nominee falls within Listing Rule 10.14.2 and therefore requires the approval of Shareholders under Listing Rule 10.14.
- 65 Resolution 8 seeks the required Shareholder approval for the issue of the Annual Equity Options under and for the purposes of Listing Rule 10.14.

Technical information required by Listing Rule 14.1A

- 66 If Resolution 8 is passed, the Company will be able to proceed with the issue of the Annual Equity Options to Mr Paul Hopper or his nominee under the Omnibus Incentive Plan. As approval pursuant to Listing Rule 7.1 is not required for the issue of the Annual Equity Options (because approval is being obtained under Listing Rule 10.14), the issue of the Annual Equity Options will not use up any of the Company's 15% annual placement capacity. Once approval is obtained pursuant to Listing Rule 10.14, the Company is entitled to rely on Listing Rule 10.12 (Exception 4) as an exception to any requirement that may otherwise apply requiring Shareholder approval under Listing Rule 10.11.
- 67 If Resolution 8 is not passed, the Company will not be able to proceed with the issue of the Annual Equity Options to Mr Paul Hopper under the Omnibus Incentive Plan and may need to agree alternative forms of remuneration with Mr Paul Hopper.

Technical information required by Listing Rule 10.15

68

Pursuant to and in accordance with the requirements of Listing Rule 10.15, the following information is provided in relation to Resolution 8:

- (a) the Annual Equity Options will be issued to Mr Paul Hopper or his nominee, who falls within the category set out in Listing Rule 10.14.2 by virtue of being an associate of Mr Paul Hopper who is a Director;
- (b) the maximum number of Annual Equity Options to be issued is 4,210,329;
- (c) the current total remuneration package for Mr Paul Hopper (excluding the value of the proposed Annual Equity Options) is \$291,042 for the year ended 30 June 2022;
- (d) other than the Annual Equity Options, the Company has previously issued Nil Options to Mr Paul Hopper or his nominee) under the Omnibus Incentive Plan;
- (e) a summary of the material terms of the Annual Equity Options are set out in Schedule 2;
- (f) the Company has chosen to issue the Annual Equity Options (as opposed to fully paid ordinary securities) to Mr Paul Hopper for the following reasons:
 - (i) the Annual Equity Options are unquoted, therefore, the issue of the Annual Equity Options has no immediate dilutionary impact on Shareholders;
 - (ii) the issue of the Annual Equity Options is a reasonable and appropriate method to provide cost effective remuneration as the non-cash form of this benefit will allow the Company to spend a greater proportion of its cash reserves on its operations than it would if alternative cash forms of remuneration were given to Mr Paul Hopper; and
 - (iii) it is not considered that there are any significant opportunity costs to the Company or benefits foregone by the Company in issuing the Annual Equity Options on the terms proposed;
- (g) the Company values the Annual Equity Options (in aggregate) to be issued to Mr Paul Hopper or his nominee at \$281,250 (being approximately \$0.0668 per Annual Equity Option) based on the Black-Scholes methodology using the closing price of 1 July 2022, exercise price per Annual Equity Option of \$0.17, life of the Annual Equity Options of 5 years, a risk free interest rate of 3.23% and assumed volatility of 100%. The above is based on inputs at 1 July 2022. This information is provided for the purposes of the applicable Listing Rule using the stated assumptions which may not apply at the time of the issue of the options and the actual value may be different. The value under accounting standards will be calculated based on inputs at the date of Shareholder approval;
- (h) if this Resolution 8 is passed, it is intended that the Annual Equity Options will be issued to Mr Paul Hopper (or his nominee) within 30 days after this Annual General Meeting, but in any event no later than 3 years after the date of this Annual General Meeting (or such later date as permitted by any ASX waiver or modification of the Listing Rules);
- (i) the issue price of the Annual Equity Options will be nil, as such no funds will be raised from the issue of the Annual Equity Options (other than in respect of funds received on exercise of the Annual Equity Options where the Cashless Exercise Facility is not used);

- (j) a summary of the material terms of the Omnibus Incentive Plan are set out in Schedule 3;
- (k) no loan is being made to Mr Paul Hopper in connection with the acquisition of the Annual Equity Options;
- (l) details of any Options issued under the Omnibus Incentive Plan will be published in the annual report of the Company relating to the period in which they were issued, along with a statement that approval for the issue was obtained under Listing Rule 10.14; and
- (m) any additional persons covered by Listing Rule 10.14 who become entitled to participate in an issue of Options under the Omnibus Incentive Plan after Resolution 8 is approved and who were not named in this Notice will not participate until approval is obtained under Listing Rule 10.14.

Directors' Recommendation

- 69 The Directors (with Mr Paul Hopper abstaining) unanimously recommend that you vote in favour of this resolution.

Resolution 9: Approval to issue Options to Director – Mr Riccardo Canevari

- 70 The Company intends to issue Mr Riccardo Canevari 12,505,088 Options pursuant to the terms of the Company's Omnibus Incentive Plan (**Annual Equity Options**).

Chapter 2E of the Corporations Act

- 71 For the purposes of Chapter 2E of the Corporations act (as summarised at paragraph 33), the issue of the Annual Equity Options to Mr Riccardo Canevari (or his nominee) constitutes giving a financial benefit and Mr Riccardo Canevari is a related party of the Company by virtue of being a Director.
- 72 The Directors (with Mr Riccardo Canevari abstaining) consider that Shareholder approval pursuant to Chapter 2E of the Corporations Act is not required in respect of the issue of Annual Equity Options, because the agreement to issue the Annual Equity Options is considered reasonable remuneration in the circumstances and was negotiated on an arm's length basis.

Listing Rule 10.14

- 73 For the purposes of Listing Rule 10.14 (as summarised at paragraph 36) the issue of the Annual Equity Options to Mr Riccardo Canevari falls within Listing Rule 10.14.1 and therefore requires the approval of Shareholders under Listing Rule 10.14.
- 74 Resolution 9 seeks the required Shareholder approval for the issue of the Annual Equity Options under and for the purposes of Listing Rule 10.14.

Technical information required by Listing Rule 14.1A

- 75 If Resolution 9 is passed, the Company will be able to proceed with the issue of the Annual Equity Options to Mr Riccardo Canevari under the Omnibus Incentive Plan. As approval pursuant to Listing Rule 7.1 is not required for the issue of the Annual Equity Options (because approval is being obtained under Listing Rule 10.14), the issue of the Annual Equity Options will not use up any of the Company's 15% annual placement capacity. Once approval is obtained pursuant to Listing Rule 10.14, the Company is entitled to rely on Listing Rule 10.12 (Exception 4) as an

exception to any requirement that may otherwise apply requiring Shareholder approval under Listing Rule 10.11.

- 76 If Resolution 9 is not passed, the Company will not be able to proceed with the issue of the Annual Equity Options to Mr Riccardo Canevari under the Omnibus Incentive Plan and may need to agree alternative forms of remuneration with Mr Riccardo Canevari.

Technical information required by Listing Rule 10.15

- 77 Pursuant to and in accordance with the requirements of Listing Rule 10.15, the following information is provided in relation to Resolution 9:

- (a) the Annual Equity Options will be issued to Mr Riccardo Canevari (or his nominee), who falls within the category set out in Listing Rule 10.14.1 by virtue of Mr Riccardo Canevari being a Director;
- (b) the maximum number of Annual Equity Options to be issued is 12,505,088;
- (c) the current total remuneration package for Mr Riccardo Canevari (excluding the value of the proposed Annual Equity Options) is \$3,232,566 for the year ended 30 June 2022. If the Annual Equity Options are issued, the total remuneration package of Mr Riccardo Canevari will increase by \$835,340 to \$4,067,906, being the value of the Annual Equity Options (based on the Black-Scholes methodology);
- (d) other than the Annual Equity Options, the Company has previously issued 8,666,678 Options to Mr Riccardo Canevari under the Omnibus Incentive Plan;
- (e) a summary of the material terms of the Annual Equity Options are set out in Schedule 2;
- (f) the Company has chosen to issue the Annual Equity Options (as opposed to fully paid ordinary securities) to Mr Riccardo Canevari for the following reasons:
 - (i) the Annual Equity Options are unquoted, therefore, the issue of the Annual Equity Options has no immediate dilutionary impact on Shareholders;
 - (ii) the issue of Annual Equity Options to Mr Riccardo Canevari will align the interests of Mr Riccardo Canevari with those of Shareholders;
 - (iii) the issue of the Annual Equity Options is a reasonable and appropriate method to provide cost effective remuneration as the non-cash form of this benefit will allow the Company to spend a greater proportion of its cash reserves on its operations than it would if alternative cash forms of remuneration were given to Mr Riccardo Canevari; and
 - (iv) it is not considered that there are any significant opportunity costs to the Company or benefits foregone by the Company in issuing the Annual Equity Options on the terms proposed;
- (g) the Company values the Annual Equity Options (in aggregate) to be issued to Mr Riccardo Canevari at \$835,340 (being approximately \$0.0668 per Annual Equity Option) based on the Black-Scholes methodology using the closing price of 1 July 2022, exercise price per Annual Equity Option of \$0.17, life of the Annual Equity Options of five years, a risk free interest rate of 3.23% and assumed volatility of 100%. The above is based on inputs at 1 July 2022. This information is provided for the purposes of the applicable Listing Rule using the stated assumptions which may not apply at the time of the issue of

the options and the actual value may be different. The value under accounting standards will be calculated based on inputs at the date of Shareholder approval;

- (h) if this Resolution 9 is passed, it is intended that the Annual Equity Options will be issued to Mr Riccardo Canevari (or his nominee) within 30 days after this Annual General Meeting, but in any event no later than 3 years after the date of this Annual General Meeting (or such later date as permitted by any ASX waiver or modification of the Listing Rules);
- (i) the issue price of the Annual Equity Options will be nil, as such no funds will be raised from the issue of the Annual Equity Options (other than in respect of funds received on exercise of the Annual Equity Options where the Cashless Exercise Facility is not used);
- (j) a summary of the material terms of the Omnibus Incentive Plan are set out in Schedule 3;
- (k) no loan is being made to Mr Riccardo Canevari in connection with the acquisition of the Annual Equity Options;
- (l) details of any Options issued under the Omnibus Incentive Plan will be published in the annual report of the Company relating to the period in which they were issued, along with a statement that approval for the issue was obtained under Listing Rule 10.14; and
- (m) any additional persons covered by Listing Rule 10.14 who become entitled to participate in an issue of Options under the Omnibus Incentive Plan after Resolution 9 is approved and who were not named in this Notice will not participate until approval is obtained under Listing Rule 10.14.

Directors' Recommendation

- 78 The Directors (with Mr Riccardo Canevari abstaining) unanimously recommend that you vote in favour of this resolution.

Resolution 10: Approval of additional 10% capacity under Listing Rule 7.1A

Listing Rule 7.1A

- 79 Listing Rule 7.1 allows the Company to issue a maximum of 15% of its capital in any 12-month period without requiring Shareholder approval. In accordance with the Listing Rule 7.1A, eligible entities (companies that are outside the S&P/ASX 300 index and that also have a market capitalisation of \$300 million or less) can issue a further 10% of the Company's share capital over a 12-month period following the Annual General Meeting (provided Shareholder approval is obtained at the Annual General Meeting) on a non-pro rata basis.
- 80 The Company falls within the eligibility criteria required by Listing Rule 7.1A.
- 81 The number of shares that may be issued (if Shareholder approval is obtained at the Annual General Meeting) will be determined in accordance with the following formula prescribed in Listing Rule 7.1A.2:

$$(A \times D) - E$$

- A** is the number of fully paid shares on issue 12 months before the date of issue or agreement:

- (A) plus the number of fully paid shares issued in the 12 months under an exception in Listing Rule 7.2 (other than exception 9, 16 or 17);
 - (B) plus the number of fully paid Shares issued in the 12 months on the conversion of convertible securities within Listing Rule 7.2 exception 9 where:
 - (I) the convertible securities were issued or agreed to be issued before the commencement of the 12 months; or
 - (II) the issue of, or agreement or issue, the convertible securities was approved, or taken under these rules to have been approved, under Listing Rule 7.1 or 7.4;
 - (C) plus the number of fully paid Shares issued in the 12 months under an agreement to issue securities within Listing Rule 7.2 exception 16 where:
 - (I) the agreement was entered into before the commencement of the 12 months; or
 - (II) the agreement or issue was approved, or taken under these rules to have been approved, under Listing Rule 7.1 or 7.4;
 - (D) plus the number of fully paid Shares issued in the 12 months with approval of holders of Shares under Listing Rule 7.1 or 7.4. This does not include an issue of fully paid Shares under the entity's 15% placement capacity without Shareholder approval;
 - (E) plus the number of partly paid Shares that became fully paid in the 12 months; and
 - (F) less the number of fully paid Shares cancelled in the 12 months.
- D** is 10%.
- E** is the number of equity securities issued or agreed to be issued under Listing Rule 7.1A.2 in the 12 months before the date of the issue or agreement to issue that are not issued with the approval of Shareholders under Listing Rule 7.4.

Technical information required by Listing Rule 7.3A

- 82 Pursuant to and in accordance with the requirements of Listing Rule 7.3A, the following information is provided in relation to Resolution 10:

Date by which the Company may issue the securities	<p>The period commencing on the date of the Annual General Meeting at which approval is obtained and expiring on the first to occur of the following:</p> <ul style="list-style-type: none"> (a) the date which is 12 months after the date of the annual general meeting at which approval is obtained; (b) the time and date of the Company's next annual general meeting; or (c) the date of the approval by holders of the Company's ordinary securities of a transaction under Listing Rules 11.1.2 or 11.2. <p>The approval under Listing Rule 7.1A will cease to be valid in the event that holders of the Company's ordinary securities approve a transaction under Listing Rules 11.1.2 or 11.2.</p>
---	--

Minimum price at which the equity securities may be issued	<p>The issue price of each Share must be no less than 75% of the VWAP for the Shares calculated over the 15 trading days on which trades in that class were recorded immediately before:</p> <ul style="list-style-type: none"> (a) the date on which the price at which the securities are to be issued is agreed; or (b) if the securities are not issued within 10 trading days of the date in paragraph (a), the date on which the securities are issued.
Purposes for which the equity securities may be issued	<p>It is the Board's current intention that any funds raised pursuant to an issue of securities will be applied towards the commercialisation of the Company's lead products. This would principally include:</p> <ul style="list-style-type: none"> (a) research and development; (a) regulatory and reimbursement approvals; (b) maintenance of intellectual property; and <p>staff and office costs, audit and compliance expenses, and ASX fees.</p>
Risk of economic and voting dilution	<p>An issue of shares under Listing Rule 7.1A involves the risk of economic and voting dilution for existing ordinary security holders. The risks include:</p> <ul style="list-style-type: none"> (a) the market price for Shares may be significantly lower on the issue date than on the date of the approval under Listing rule 7.1A; and (b) the equity securities may be issued at a price that is at a discount to the market price for the Shares on the issue date. <p>In accordance with Listing Rule 7.3A.4 a table describing the notional possible dilution, based upon various assumptions as stated, is set out below.</p>
Details of the Company's allocation policy for issues under approval	<p>The Company's allocation policy is dependent on the prevailing market conditions at the time of any proposed issue pursuant to Listing Rule 7.1A. The identity of the allottees will be determined on a case-by-case basis having regard to the factors including but not limited to the following:</p> <ul style="list-style-type: none"> (a) the methods of raising funds that are available to the Company including but not limited to, rights issues or other issues in which existing security holders can participate; (b) the effect of the issue of the Listing Rule 7.1A shares on the control of the Company; (c) the financial situation and solvency of the Company; and (d) advice from corporate, financial and broking advisers (if applicable). <p>The allottees under the Listing Rule 7.1A facility have not been determined as at the date of this Notice of Meeting but may include existing substantial Shareholders and/or new Shareholders who are not related parties or associates of a related party of the Company.</p>
Previous approvals and issuances under Listing Rule 7.1A	<p>This is the Company's first annual general meeting since being listed on the ASX. Accordingly, no previous approvals have been sought by the Company under Listing Rule 7.1A. As such, the Company has not issued any Equity Securities in reliance on Listing Rule 7.1A to date.</p>

Information under Listing Rule 7.3A.4

- 83 The table below shows the dilution of existing Shareholders on the basis of the current market price of Shares and the current number of ordinary securities for variable "A" calculated in accordance with the formula in Listing Rule 7.1A.2 as at the date of this Notice of Meeting.
- 84 The table also shows:

- (a) two examples where variable "A" has increased, by 50% and 100%. Variable "A" is based on the number of ordinary securities the Company has on issue. The number of ordinary securities on issue may increase as a result of issues of ordinary securities that do not require Shareholder approval (for example, a pro rata entitlements issue or scrip issued under a takeover offer) or future specific placements under Listing Rule 7.1 that are approved at a future Shareholders' meeting; and
- (b) two examples of where the issue price of ordinary securities has decreased by 50% and increased by 100% as against the current market price.

Variable "A" in ASX Listing Rule 7.1A.2	Dilution		
	50% decrease in Issue Price \$0.0825	Current Market Price \$0.165	50% Increase in Issue Price \$0.2475
Current Variable A 253,333,557 Shares	10% Voting Dilution 25,333,355 Shares		
Funds raised	\$2,090,002	\$4,180,004	\$6,270,005
50% increase in current Variable A 380,000,336 Shares	10% Voting Dilution 38,000,033 Shares		
Funds raised	\$3,135,003	\$6,270,005	\$9,405,008
100% increase in current Variable A 506,667,114 Shares	10% Voting Dilution 50,666,711 Shares		
Funds raised	\$4,180,004	\$8,360,007	\$12,540,011

*Note: Current Variable A refers to the calculation required by Listing Rule 7.3A.4 which, in the Company's case, equates to the current issued share capital of the Company.

85 The table has been prepared on the following assumptions:

- (a) the Company issues the maximum number of Shares available under the 10% Listing Rule 7.1A approval;
- (b) no options are exercised to convert into Shares before the date of the issue of the Shares available under Listing Rule 7.1A;
- (c) the 10% voting dilution reflects the aggregate percentage dilution against the issued share capital at the time of issue. This is why the voting dilution is shown in each example as 10%;
- (d) the table does not show an example of dilution that may be caused to a particular Shareholder by reason of a share issue under Listing Rule 7.1A, based on that Shareholder's holding at the date of the Annual General Meeting;
- (e) the table shows only the effect of issues of equity securities under Listing Rule 7.1A, not under the 15% placement capacity under Listing Rule 7.1;
- (f) the issue of Shares under Listing Rule 7.1A consists only of Shares; and

(g) the issue price is \$0.165, being the closing price of the shares on ASX on 6 October 2022.

86 As at the date of the Notice of Meeting, the Company has on issue 253,333,557 Shares. Subject to Shareholder approval being obtained for Resolution 10, the Company will have capacity to issue the following equity securities as at the date of the Annual General Meeting:

(a) 38,314,987 Shares (under Listing Rule 7.1); and

(b) 25,543,325 Shares (under Listing Rule 7.1A).¹

87 Listing Rule 7.1A requires Resolution 10 to be passed as a special resolution. A special resolution needs approval by at least 75% of the votes cast by members entitled to vote on the resolution.

Technical information required by Listing Rule 14.1A

88 If Resolution 10 is passed, the Company will be able to issue Equity Securities up to the combined 25% limit in Listing Rules 7.1 (15%) and 7.1A (10%) without any further Shareholder approval.

89 If Resolution 10 is not passed, the Company will not be able to access the additional 10% capacity to issue Equity Securities without Shareholder approval under Listing Rule 7.1A, and will remain subject to the 15% limit on issuing Equity Securities without Shareholder approval set out in Listing Rule 7.1.

Directors' recommendation

90 The Directors unanimously recommend that Shareholders vote in favour of this resolution.

Resolutions 11: Renewal of Omnibus Incentive Plan

91 A key foundation of the Company's equity incentive programme is the Company's Omnibus Incentive Plan

92 The Omnibus Incentive Plan is designed to:

(a) align employee incentives with shareholders' interests;

(b) assist employee attraction and retention; and

(c) encourage share ownership by employees.

93 The Omnibus Incentive Plan has been adopted since the Company's listing in November 2021.

Listing Rules

94 ASX Listing Rule 7.1 allows the Company to issue a maximum of 15% of its capital in any 12-month period without requiring shareholder approval. Pursuant to Listing Rule 7.2, Exception 13, an issue under an employee incentive plan will not count toward a company's 15% limit provided the plan was approved by shareholders within three years before the date of the securities being issued. Approval is therefore sought in respect of the Omnibus Incentive Plan under that rule.

¹ The actual number of Shares the Company will have capacity to issue under Listing Rule 7.1A may vary and will be determined at the date of issue in accordance with Listing Rule 7.3A.4 (as illustrated in the table above).

- 95 If Resolution 11 is not approved, any issuances of securities by the Company under the Omnibus Incentive Plan will count towards the Company's placement capacity under Listing Rule 7.1 (unless such securities are issued with shareholder approval under a different Listing Rule).

Corporations Act

- 96 In respect of Resolution 11, Shareholders are also being asked to approve the ability for the Board to be able to exercise certain discretions under the Omnibus Incentive Plan in relation to the treatment of unvested or unexercisable awards that may have been granted under the Omnibus Incentive Plan.
- 97 Under the Omnibus Incentive Plan, the Company has the flexibility to offer performance rights, options, shares and share appreciation rights.

Listing Rules

- 98 For the purposes of Listing Rule 7.2 exception 13:
- (a) 36,211,332 unlisted options have been issued under the Omnibus Incentive Plan since the Omnibus Incentive Plan was adopted by the Company, with 19,433,356 unlisted options having previously been disclosed in the prospectus dated 14 October 2021 and the supplementary prospectus dated 28 October 2021 and issued upon reliance of Listing Rule 7.2 exception 16; and
 - (b) the maximum number of securities proposed to be issued under the Omnibus Incentive Plan within the three-year period from the date of the passing of this resolution is 31,929,156 (which currently represents 12.5% of the Company's Share capital). This number is not intended to be a prediction of the actual number of securities to be issued by the Company, simply a ceiling for the purposes of Listing Rule 7.2 (Exception 13(b)).
- 99 A copy of the Omnibus Incentive Plan is set out in Schedule 3 to this Explanatory Memorandum.

Corporations Act

- 100 Shareholders are also being asked to approve the ability for the Board to be able to exercise certain discretions under the Omnibus Incentive Plan in relation to the treatment of unvested or unexercisable awards that may have been granted under the Omnibus Incentive Plan.
- 101 The Corporations Act provides that the Company may only give a person a benefit in connection with their ceasing to hold a managerial or executive office in the Company or its related bodies corporate if it is approved by Shareholders or an exemption applies (for example, where the benefit together with other benefits does not exceed the base salary of the relevant person as set out in section 200F Corporations Act).
- 102 The term 'benefit' has a wide operation and may include (for example) the accelerated vesting of awards issued under the Omnibus Incentive Plan. Under the terms of the Omnibus Incentive Plan, the Board has the discretion to determine that some, or all, of those awards that have not vested or are not otherwise exercisable at the time an eligible participant ceases employment with the Company either vest, become exercisable or otherwise waive restrictions on the awards. If an eligible participant who holds, or has held, a managerial or executive office within the meaning of section 200B ceases employment with the Company, that eligible participant may be entitled to have any awards issued to them vest, or otherwise become exercisable where the awards were not otherwise (at the discretion of the Board). This constitutes a 'benefit' for the purposes of section 200B Corporations Act.

- 103 Advance shareholder approval is therefore being sought, for the purposes of sections 200B and 200E Corporations Act, to provide benefits which may otherwise be prohibited under section 200B Corporations Act. If shareholder approval is obtained, it will give the Board maximum flexibility to deal with the unvested or unexercisable awards under the plan granted to executives or key personnel who cease employment.
- 104 Shareholders are not being asked to approve any increase in the remuneration or benefits payable to relevant personnel, nor any variations to the existing discretions of the Board. Approval is sought in relation to both current and future personnel who hold or have held during the three years prior to cessation of employment a managerial or executive office in the Company or a related body corporate.
- 105 The amount and value of the termination benefits for which the Company is seeking approval is the maximum potential benefit that could be provided under the Omnibus Incentive Plan, in order to provide the Board with the discretion to determine the most appropriate termination package for the outgoing executives or key personnel. There is no obligation for the Board to exercise this discretion. Exercise of the discretion will depend on factors such as the participant's performance, contribution and tenure. The amount and value of any consequent termination benefits that may be received as a result of early exercise of the awards upon cessation of employment cannot be ascertained in advance. This is because various matters, events and circumstances will or are likely to affect the calculation of the amount and value, including:
- (a) the circumstances of the participant's cessation of employment (for example, whether cessation of employment arises due to resignation, retirement or redundancy);
 - (b) the terms contained within the invitation to participate (such as the applicable vesting conditions);
 - (c) number of unvested or unexercisable awards held by the relevant eligible participant prior to cessation of employment;
 - (d) the market price of the Company's shares on the ASX at the relevant time; and
 - (e) any other factors that the Board determines to be relevant when exercising its discretion under the Plan.
- 106 It can be reasonably anticipated that aspects of the Omnibus Incentive Plan may be amended from time to time in line with market practice and changing governance standards. Where relevant, these changes will be reported in the Company's Remuneration Report. However, it is intended that this approval will remain valid for Board discretions exercised under the Omnibus Incentive Plan, provided that at the time the discretion is exercised the Omnibus Incentive Plan rules contain a discretion for the Board to vest all or a pro rata portion of a participant's unvested awards or to allow them to continue on foot on the terms of the Omnibus Incentive Plan rules.

Directors' recommendation

- 107 The Directors abstain, in the interest of good corporate governance, from making a recommendation in relation to this resolution.

Schedule 1

Material Terms of the Incentive Options

Issue price	The Incentive Options were issued for nil consideration.
Vesting conditions	Vesting over 24 months from issue date (following this Annual General Meeting)
Vesting date	<p>The Incentive Options will vest as follow:</p> <p>(a) in relation to the Incentive Options issued to Ms Hester Larkin:</p> <p>(i) 627,001 Incentive Options will vest upon issue date (following this Annual General Meeting);</p> <p>(ii) 627,001 Incentive Options will vest at 12 months from issue date (12 months after this Annual General Meeting);</p> <p>(iii) 646,000 Incentive Options will vest at 24 months from issue date (24 months after this Annual General Meeting); and</p> <p>(b) in relation to the Incentive Options issued to Dr Leila Alland:</p> <p>(i) 627,001 Incentive Options will vest upon issue date (following this Annual General Meeting);</p> <p>(ii) 627,001 Incentive Options will vest at 12 months from issue date (12 months after this Annual General Meeting);</p> <p>(iii) 646,000 Incentive Options will vest at 24 months from issue date (24 months after this Annual General Meeting).</p>
Entitlement	Each vested Incentive Option will entitle the holder to subscribe for one Share upon payment of the Exercise Price.
Exercise price	The amount payable upon exercise of each Incentive Option will be \$0.60 (Exercise Price) or exercisable utilising the Cashless Exercise Facility under the Omnibus Incentive Plan (See Schedule 3).
Expiry date	The Incentive Options will expire 4 years from the date of issue (Expiry Date).
Exercise period	The Incentive Options are exercisable at any time during the period commencing on and from the relevant vesting date and ending on the Expiry Date (Exercise Period).
Notice of exercise	The Options may be exercised during the Exercise Period by notice in writing to the Company (Notice of Exercise).
Exercise date	A Notice of Exercise is only effective on and from the later of the date of receipt of the Notice of Exercise and the date of receipt of the payment of the Exercise Price for each Incentive Option being exercised in cleared funds.

Quotation	The Incentive Options will not be quoted on ASX. The Company intends to apply to ASX for quotation of any Shares acquired on exercise of the Incentive Options.
Ranking of Shares	All Shares issued pursuant to the exercise of Incentive Options will, subject to the Constitution of the Company, rank in all respects (other than in respect of dividends, rights issues or bonus issues declared prior to allotment) equally with the existing Shares at the date of issue and allotment.
Reconstruction of capital	If there is a reorganisation (including consolidation, sub-division, reduction or return) of the share capital of the Company, the rights attaching to the Incentive Options will be changed to the extent necessary to comply with the Listing Rules applying to a re-organisation of capital at the time of the re-organisation.
Participation in new issues	The Incentive Options do not entitle the holder to participate in any new issues by the Company without exercising the options.
Change in exercise price	<p>The Incentive Options do not confer on the holder any rights to a change in the Exercise Price or a change to the number of underlying securities over which the Incentive Options can be exercised except:</p> <ul style="list-style-type: none"> (a) in the case of a pro rata issue to the holders of Shares (except a bonus issue) in which case the Exercise Price of each Incentive Option shall be reduced in accordance with the formula contained in Listing Rule 6.22.2; and (b) in the case of a bonus issue to the holders of Shares, in which case the number of Shares over which each option is exercisable shall be increased by the number of Shares which the holder of the option would have received if the option had been exercised before the record date for the bonus issue.
Transferability	The Incentive Options will not be transferable.
Escrow	The Incentive Options will be escrowed from 24 months from the date of issue.
Plan	The Incentive Options will be issued under the terms of the Omnibus Incentive Plan (Schedule 3) and are subject to Shareholder approval.

Schedule 2

Material Terms of the Annual Equity Options

Issue price	The Annual Equity Options were issued for nil consideration.
Vesting conditions	Vesting over 36 months from 1 July 2022 (following this Annual General Meeting)
Vesting date	<p>The Incentive Options will vest as follow:</p> <p>(a) in relation to the Annual Equity Options issued to Mr Paul Hopper:</p> <p>(i) 1,403,303 Annual Equity Options will vest on 1 July 2023 (following this Annual General Meeting);</p> <p>(ii) 1,403,303 Annual Equity Options will vest on 1 July 2024;</p> <p>(iii) 1,403,723 Annual Equity Options will vest on 1 July 2025; and</p> <p>(b) in relation to the Annual Equity Options issued to Mr Riccardo Canevari:</p> <p>(i) 4,167,946 Annual Equity Options will vest on 1 July 2023 (following this Annual General Meeting);</p> <p>(ii) 4,167,946 Annual Equity Options will vest on 1 July 2024;</p> <p>(iii) 4,169,196 Annual Equity Options will vest on 1 July 2025.</p>
Entitlement	Each vested Annual Equity Option will entitle the holder to subscribe for one Share upon payment of the Exercise Price.
Exercise price	The amount payable upon exercise of each Annual Equity Option will be \$0.17 (Exercise Price) or exercisable utilising the Cashless Exercise Facility under the Omnibus Incentive Plan (See Schedule 3).
Expiry date	The Annual Equity Options will expire 5 years from the date of issue (Expiry Date).
Exercise period	The Annual Equity Options are exercisable at any time during the period commencing on and from the relevant vesting date and ending on the Expiry Date (Exercise Period).
Notice of exercise	The Options may be exercised during the Exercise Period by notice in writing to the Company (Notice of Exercise).
Exercise date	A Notice of Exercise is only effective on and from the later of the date of receipt of the Notice of Exercise and the date of receipt of the payment of the Exercise Price for each Incentive Option being exercised in cleared funds.
Quotation	The Annual Equity Options will not be quoted on ASX. The Company intends to apply to ASX for quotation of any Shares acquired on exercise of the Incentive Options.
Ranking of Shares	All Shares issued pursuant to the exercise of Annual Equity Options will, subject to the Constitution of the Company, rank in all respects

	(other than in respect of dividends, rights issues or bonus issues declared prior to allotment) equally with the existing Shares at the date of issue and allotment.
Reconstruction of capital	If there is a reorganisation (including consolidation, sub-division, reduction or return) of the share capital of the Company, the rights attaching to the Incentive Options will be changed to the extent necessary to comply with the Listing Rules applying to a re-organisation of capital at the time of the re-organisation.
Participation in new issues	The Annual Equity Options do not entitle the holder to participate in any new issues by the Company without exercising the options.
Change in exercise price	<p>The Annual Equity Options do not confer on the holder any rights to a change in the Exercise Price or a change to the number of underlying securities over which the Incentive Options can be exercised except:</p> <ul style="list-style-type: none"> (a) in the case of a pro rata issue to the holders of Shares (except a bonus issue) in which case the Exercise Price of each Incentive Option shall be reduced in accordance with the formula contained in Listing Rule 6.22.2; and (b) in the case of a bonus issue to the holders of Shares, in which case the number of Shares over which each option is exercisable shall be increased by the number of Shares which the holder of the option would have received if the option had been exercised before the record date for the bonus issue.
Transferability	The Annual Equity Options will not be transferable.
Plan	The Annual Equity Options will be issued under the terms of the Omnibus Incentive Plan (Schedule 3) and are subject to Shareholder approval.

Schedule 3

Materials terms of the Omnibus Incentive Plan

Eligibility	The Board may designate a full-time or permanent part-time employee of the Company, contractor or consultant as an eligible participant for the purposes of the Plan.
Form of equity	<p>Awards of fully paid ordinary shares, options, performance rights and share appreciation rights can be made under the Plan.</p> <p>Shares can be granted to eligible employees under a free grant (receiving an allocation of shares for no consideration) or salary contribution agreement.</p> <p>An option confers a right to acquire a share during the exercise period, subject to the satisfaction of any vesting conditions, the payment of the exercise price for the option set out in the offer, and otherwise in the manner required by the Board and specified by the offer.</p> <p>A performance right confers an entitlement to be issued, transferred or allocated one share after the vesting date, subject to any disposal restrictions, the satisfaction of the vesting conditions, and any other requirements contained in the offer.</p> <p>A share appreciation right confers an entitlement to be issued, transferred or allocated the number of shares calculated under the terms of the Plan after the vesting date, subject to any disposal restrictions, the satisfaction of the vesting conditions and any other requirement contained in the offer. The Board may decide, in its absolute discretion to substitute the issue, transfer or allocation of these shares for the payment of a cash amount.</p>
Terms of award	A grant of an award under the Plan is subject to both the rules of the Plan and the terms of the specific offer.
Exercise price	Exercise price is the amount set out in the offer and means the price payable on exercise of an option to acquire the underlying share.
Cashless Exercise Facility	<p>The Board may determine and specify in an offer that a participant may elect to pay the exercise price for an option by setting off the exercise price against the number of shares which they are entitled to receive upon exercise (Cashless Exercise Facility). By using the Cashless Exercise Facility, the participant will receive shares to the value of the surplus after the exercise price has been set off.</p> <p>If a participant elects to use the Cashless Exercise Facility, the participant will only be issued that number of shares (rounded down to the nearest whole number) as are equal to the value of the difference between the exercise price otherwise payable for the options and the then market value of the shares at the time of exercise (determined based on the volume weighted average price for a share traded on the ASX during the 7 day period up to and including the exercise date).</p>
Exercise	<p>Subject to the satisfaction of vesting conditions, a participant may exercise an option at any time in the exercise period by delivering a notice of exercise and paying the exercise price to the Company.</p> <p>A share issued, transferred or allocated on the exercise of any option or under a performance right or share appreciation right after vesting will rank equally with all existing shares of that class from the date of allotment, subject to the terms of the trust deed constituting the trust (if relevant).</p>

	<p>If the shares are officially quoted by ASX, the Company will apply to ASX for official quotation of any shares issued, transferred or allocated to a participant (unless already quoted).</p>
Change of control	<p>Unexercised Options</p> <p>If a specified change of control trigger event (e.g. a person acquiring voting power in more than 50% of the ordinary shares in the Company, lodgment with ASIC of an order of the court in connection with a scheme of arrangement, the Company disposes of the whole or a substantial part of its assets or undertaking) occurs, the Company may:</p> <ul style="list-style-type: none"> (a) buy-back options held by a participant; (b) arrange for options or other rights to acquire shares or other equity interests in the bidder to be granted to the participants on substantially the same terms as the options, but with any appropriate and reasonable adjustments decided by the Board to ensure the participants are not materially financially disadvantaged; (c) allow the options to continue in accordance with their terms; (d) allow the options to vest immediately and be exercised by a participant (irrespective of the whether any vesting conditions are satisfied); or (e) proceed with a combination of any of the above. <p>Performance rights and share appreciation rights</p> <p>Unless the Board decides otherwise, if a change of control trigger event occurs, the vesting date of all performance rights and share appreciation rights is the date on which the change of control trigger event occurs or another date decided by the Board.</p> <p>After the occurrence of a change of control trigger event, the Board must decide whether the performance rights and share appreciation rights (or a pro rata proportion of performance rights and share appreciation rights) vest on the changed vesting date.</p> <p>If the Board decides that performance rights and share appreciation rights do vest, the Company must either:</p> <ul style="list-style-type: none"> (a) issue, transfer or allocate Shares to Participants as soon as reasonably practicable; (b) pay to the Participant a cash payment for the Performance Rights and Share Appreciation Rights; (c) arrange for shares or other equity interests to be issued in the Bidder in lieu of Shares on the terms decided by the Board as soon as reasonably practicable; or (d) proceed with a combination of these alternatives. <p>If the Board decides that performance rights and share appreciation rights do not vest:</p> <ul style="list-style-type: none"> (a) the Board may arrange for rights in the bidder to be granted to the participant on terms decided by the Board and the performance rights and share appreciation rights will immediately lapse; or (b) those performance rights and share appreciation rights immediately lapse, unless the Board decides otherwise. <p>Shares</p> <p>The Board may specify in the offer a particular treatment applicable to shares upon the occurrence of a change of control trigger event.</p> <p>The Company and the participant agree that a participant may be provided with shares in the bidder in substitution for the shares, on substantially the</p>

	same terms as the shares, but with appropriate adjustments as to the number and type of shares.
Lapse	<p>If one of the following events occurs:</p> <ul style="list-style-type: none"> (a) the eligible participant is lawfully terminated from employment with the group or consultancy arrangement with the group; (b) the eligible participant resigns or vacates from the Board, employment or consultancy with the group; or (c) the eligible participant is made redundant, <p>then, subject to the Board deciding otherwise, the eligible participant's options, performance rights and share appreciation rights will lapse in the following manner:</p> <ul style="list-style-type: none"> (a) if the event occurs between the grant date and vesting, performance rights and share appreciation rights lapse immediately; (b) if the event occurs on or before the vesting date, the options lapse immediately; and (c) if the event occurs during the exercise period, the expiry date is adjusted to the date set out in the offer or a later date decided by the Board. <p>In the event of death or disability (inability to perform normal duties) of the eligible participant, subject to the Board deciding otherwise:</p> <ul style="list-style-type: none"> (a) if the event occurs between the grant date and vesting, performance rights and share appreciation rights do not lapse; (b) if the event occurs on or before the vesting date, options lapse 90 days after the death or disability; and (c) if the event occurs during the exercise period, there is no adjustment and the representative of the eligible participant's estate may exercise the options before the expiry date. <p>In the event that the eligible participant loses control of their permitted nominee and the awards are not transferred to the eligible participant in accordance with the terms of the Plan, subject to the Board deciding otherwise:</p> <ul style="list-style-type: none"> (a) the performance rights lapse immediately if the event occurs between grant date and vesting; (b) the share appreciation rights lapse immediately (unless they are transferred to the eligible participant) if the event occurs between grant date and vesting, or (c) options lapse immediately if the event occurs on or before the vesting date or during the exercise period. <p>Unless the Board decides otherwise or as otherwise specified in an offer, an option that has not been exercised on or before the expiry date lapses at 5.00pm AEST on the day after the expiry date.</p>
Share issues	<p>Participation in further issues</p> <p>A participant (other than a participant that has been issued, transferred or allocated shares in accordance with an award) can only participate in a new issue of shares if:</p> <ul style="list-style-type: none"> (a) the option has been exercised; or (b) shares have been issued, transferred or allocated for their performance rights or share appreciation rights.

	<p>If a pro rata or cash issue of securities is awarded by the Company, the number of shares:</p> <ul style="list-style-type: none"> (a) to be issued on exercise of an option and the Exercise Price; or (b) over which a Performance Right or Share appreciation right exists, will be adjusted as specified in the Listing Rules and written notice will be given to the participant. <p>Reconstructions</p> <p>If there is any reconstruction of the issued share capital of the Company (including consolidation, sub-division, reduction or return), the number of Shares:</p> <ul style="list-style-type: none"> (a) issued to a participant under the Plan; (b) to be issued on exercise of an option; or (c) over which a performance right or share appreciation right exists, will be adjusted to the extent necessary to comply with the Listing Rules applying to a reorganisation of capital.
Transfer of awards	<p>Participants may only:</p> <ul style="list-style-type: none"> (a) create a Security Interest in; or (b) transfer, assign, dispose or otherwise deal with, <p>awards, or any interest in awards, with the prior written consent of the Board.</p> <p>The transmission of awards to a legal representative of an eligible participant following their death may be made without prior written consent of the Board.</p> <p>The offer may contain a disposal restriction which could restrict the creation of a security interest in, or the transfer, assignment disposal or otherwise dealing with, a share issued, transferred or allocated to the participant on acceptance, exercise or vesting of an award.</p>
Dividends	<p>A participant does not have the right to participate in dividends on shares until the shares are issued, transferred or allocated, including:</p> <ul style="list-style-type: none"> (a) on the exercise of an option; or (b) after vesting of the performance rights or share appreciation rights.
Voting rights	<p>A participant does not have the right to vote in respect of an option, a performance right or a share appreciation right.</p>
Administration of the Plan	<p>The decision of the Board as to the interpretation, effect or application of the Plan is final. In exercising a power or discretion conferred on it by the Plan, the Board is not under a fiduciary or other obligation to any other person.</p> <p>Where the Board, the Company, or their delegates may exercise any right or discretion to make a decision, it may do so in its absolute discretion, conditionally or unconditionally, and without being required to give reasons or act reasonably.</p> <p>The Board may delegate any of its functions and powers conferred on it by the Plan to a committee made up of a person or persons capable of performing those functions and exercising those powers. The Board may make policy and regulations for the operation of the Plan and may delegate functions to an appropriate service provider or employee capable of performing those functions and implementing those policies.</p> <p>The Board or committee may take and rely upon independent professional or expert advice on the exercise of their powers or discretions.</p>

Amendment	<p>The Board must not make any amendment to the Plan which would have the effect of materially adversely affecting or prejudicing the rights of any Participant holding awards at that time. This does not apply to amendments:</p> <ul style="list-style-type: none"> (a) which comply with the Constitution, Corporations Act, Listing Rules or any other law affecting the maintenance or operation of the Plan; (b) which correct a manifest error; or (c) which address potential adverse tax implications affecting the Plan arising from changes to laws relating to taxation or the interpretation of laws relating to taxation. <p>Subject to this restriction, the Board may amend the Plan in any manner it decides.</p>
Termination	<p>The Plan may be terminated or suspended at any time by the Board and that termination or suspension will not have any effect on or prejudice the rights of any Participant holding awards at that time.</p>
Trust	<p>The Company may create a trust for the purpose of holding, transferring or allocating awards (or shares on exercise or vesting of an award) in connection with the Plan and any other employee incentive plan operated by the Company or its subsidiaries from time to time.</p>

Glossary

Annual General Meeting or Meeting	means the Company's annual general meeting the subject of this Notice of Meeting.
Annual Report	means the 2022 annual report of the Company.
ASIC	means the Australian Securities and Investments Commission.
ASX	means ASX Limited ACN 008 624 691 or the securities exchange operated by it (as the case requires).
Board	means the board of directors of the Company.
Cashless Exercise Facility	has the meaning given to it in Schedule 3.
Company	means Radiopharm Theranostics Limited ACN 647 877 889.
Company Secretary	means Phillip Hains and Nathan Jong.
Company's Constitution	means the constitution of the Company.
Corporations Act	means the <i>Corporations Act 2001</i> (Cth).
Corporations Regulations	means the <i>Corporations Regulations 2001</i> (Cth).
Directors	means the directors of the Company.
Equity Securities	has the meaning set out in the Listing Rules.
Explanatory Memorandum	means the explanatory memorandum attached to the Notice of Meeting.
Key Management Personnel	means those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, including any Director (whether executive or otherwise).
Listing Rules or LR	means the listing rules of ASX.
Notice of Meeting	means the notice of meeting and includes the Explanatory Memorandum.
Omnibus Incentive Plan (or Plan)	means the Company's equity incentive program.
Options	means an option to subscribe for a Share.
Remuneration Report	means the section of the Directors' report for the 2022 financial year that is included under section 300A(1) Corporations Act.
Resolution	means a resolution of this Annual General Meeting of the Company.
Shares	means the existing fully paid ordinary shares in the Company.
Shareholder	means a person who is the registered holder of Shares.
Sophisticated Investors	means sophisticated and professional investors as those terms are defined in the Corporations Act.
VWAP	means volume weighted average price.

Proxy Voting Form

If you are attending the virtual Meeting please retain this Proxy Voting Form for online Securityholder registration.

Holder Number:

Your proxy voting instruction must be received by **10.00am (Sydney time) on Monday, 14 November 2022**, being not later than 48 hours before the commencement of the Meeting. Any Proxy Voting instructions received after that time will not be valid for the scheduled Meeting.

SUBMIT YOUR PROXY

Complete the form overleaf in accordance with the instructions set out below.

YOUR NAME AND ADDRESS

The name and address shown above is as it appears on the Company's share register. If this information is incorrect, and you have an Issuer Sponsored holding, you can update your address through the investor portal: <https://investor.automic.com.au/#/home> Shareholders sponsored by a broker should advise their broker of any changes.

STEP 1 – APPOINT A PROXY

If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that Individual or body corporate. A proxy need not be a Shareholder of the Company. Otherwise if you leave this box blank, the Chair of the Meeting will be appointed as your proxy by default.

DEFAULT TO THE CHAIR OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote these proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Voting Form, including where the Resolutions are connected directly or indirectly with the remuneration of KMP.

STEP 2 - VOTES ON ITEMS OF BUSINESS

You may direct your proxy how to vote by marking one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF SECOND PROXY

You may appoint up to two proxies. If you appoint two proxies, you should complete two separate Proxy Voting Forms and specify the percentage or number each proxy may exercise. If you do not specify a percentage or number, each proxy may exercise half the votes. You must return both Proxy Voting Forms together. If you require an additional Proxy Voting Form, contact Automic Registry Services.

SIGNING INSTRUCTIONS

Individual: Where the holding is in one name, the Shareholder must sign.

Joint holding: Where the holding is in more than one name, all Shareholders should sign.

Power of attorney: If you have not already lodged the power of attorney with the registry, please attach a certified photocopy of the power of attorney to this Proxy Voting Form when you return it.

Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you.

Email Address: Please provide your email address in the space provided.

By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible) such as a Notice of Meeting, Proxy Voting Form and Annual Report via email.

CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate 'Appointment of Corporate Representative' should be produced prior to admission. A form may be obtained from the Company's share registry online at <https://automic.com.au>.

Lodging your Proxy Voting Form:

Online:

Use your computer or smartphone to appoint a proxy at

<https://investor.automic.com.au/#/login>

or scan the QR code below using your smartphone

Login & Click on 'Meetings'. Use the Holder Number as shown at the top of this Proxy Voting Form.



BY MAIL:

Automic
GPO Box 5193
Sydney NSW 2001

IN PERSON:

Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

BY EMAIL:

meetings@automicgroup.com.au

BY FACSIMILE:

+61 2 8583 3040

All enquiries to Automic:

WEBCHAT: <https://automicgroup.com.au/>

PHONE: 1300 288 664 (Within Australia)
+61 2 9698 5414 (Overseas)

